IP37-22: An open-label Phase I/II study to assess the safety and efficacy of photodynamic therapy using the SpectraCure P18 System with verteporfin for the treatment of recurrent prostate cancer

IP37-22: An open-label Phase I/II study to assess the safety and efficacy of photodynamic therapy using the SpectraCure P18 System with verteporfin for the treatment of recurrent prostate cancer

Saturday, May 16, 2026 1:00 PM to 3:00 PM · 1 hr. 59 min. (America/New_York)
145AB
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!